RecruitingPhase 3NCT06023706

Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.

Phase 3 Confirmatory, Randomised 1:1 Double-blind, Placebo-controlled Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.

Sponsor

Nantes University Hospital

Enrollment

188 participants

Start Date

Nov 8, 2023

Study Type

INTERVENTIONAL

Conditions

Neuropathic Pain Coccygodynia Coccyx Disorder

Summary

The primary objective is to demonstrate the analgesic effect at day 60 of 8% capsaicin patch (Qutenza) for the treatment of patients with coccygodyinia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Capsaicin 179 Mg Cutaneous Patch and a drug called Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2) for people with coccygodynia, coccyx disorder, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.